{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:44:13Z","timestamp":1783651453917,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.euroneuro.2012.08.013","type":"journal-article","created":{"date-parts":[[2012,9,11]],"date-time":"2012-09-11T23:47:38Z","timestamp":1347407258000},"page":"887-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment"],"prefix":"10.1016","volume":"23","author":[{"given":"Antonio","family":"Drago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Giegling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Friedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Konte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"De Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans H.","family":"Stassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.euroneuro.2012.08.013_bib2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/schbul\/sbn114","article-title":"Pharmacogenetics in psychiatry: are we ready for widespread clinical use?","volume":"34","author":"Arranz","year":"2008","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.euroneuro.2012.08.013_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.mp.4002009","article-title":"Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research","volume":"12","author":"Arranz","year":"2007","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2012.08.013_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1385\/NMM:5:1:109","article-title":"Bipolar disorder and schizophrenia: convergent molecular data","volume":"5","author":"Berrettini","year":"2004","journal-title":"Neuromol. Med."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.08.013_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1819.2010.02168.x","article-title":"Pharmacogenomics of antipsychotics efficacy for schizophrenia","volume":"65","author":"Cacabelos","year":"2011","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"2\u20133","key":"10.1016\/j.euroneuro.2012.08.013_bib7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.schres.2005.03.008","article-title":"Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia","volume":"77","author":"Gharabawi","year":"2005","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.euroneuro.2012.08.013_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jpsychires.2009.11.004","article-title":"Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment","volume":"44","author":"Giegling","year":"2010","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.08.013_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pnpbp.2010.08.029","article-title":"Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects","volume":"35","author":"Giegling","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2012.08.013_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.biopsych.2009.08.030","article-title":"Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches","volume":"67","author":"Ikeda","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.08.013_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.euroneuro.2012.08.013_bib1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/qjmed\/hcp115","article-title":"Genetics and the general physician: insights, applications and future challenges","volume":"102","author":"Knight","year":"2009","journal-title":"QJM"},{"issue":"8","key":"10.1016\/j.euroneuro.2012.08.013_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/mp.2008.56","article-title":"Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study","volume":"14","author":"Lavedan","year":"2009","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2012.08.013_bib14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/schbul\/sbn050","article-title":"Approaches for unraveling the joint genetic determinants of schizophrenia and bipolar disorder","volume":"34","author":"Lin","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2012.08.013_bib22","first-page":"1","article-title":"Modulation of haloperidol-induced patterns of the transcription factor Nur77 and Nor-1 expression by serotonergic and adrenergic drugs in the mouse brain","author":"Maheux","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2012.08.013_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/mp.2009.89","article-title":"Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics","volume":"16","author":"McClay","year":"2011","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2012.08.013_bib17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1460-9568.2008.06109.x","article-title":"Metabotropic glutamate receptor 1 (mGluR1) and 5 (mGluR5) regulate late phases of LTP and LTD in the hippocampal CA1 region in vitro","volume":"27","author":"Neyman","year":"2008","journal-title":"Eur. J. Neurosci."},{"issue":"47","key":"10.1016\/j.euroneuro.2012.08.013_bib18","doi-asserted-by":"crossref","first-page":"12383","DOI":"10.1523\/JNEUROSCI.1662-08.2008","article-title":"The activity-regulated cytoskeletal-associated protein (Arc\/Arg3.1) is required for memory consolidation of pavlovian fear conditioning in the lateral amygdala","volume":"28","author":"Ploski","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2012.08.013_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2011.03.005","article-title":"Mechanisms of antidepressant action: an integrated dopaminergic perspective","author":"Porcelli","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2012.08.013_bib16","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1523\/JNEUROSCI.4037-06.2007","article-title":"Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus","volume":"27","author":"Rex","year":"2007","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.euroneuro.2012.08.013_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/JCP.0b013e3181fbfac4","article-title":"Association between the 1291-C\/G polymorphism in the adrenergic \u03b1-2a receptor and the metabolic syndrome","volume":"30","author":"Risselada","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2012.08.013_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0006-3223(03)00165-3","article-title":"Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD)","volume":"53","author":"Sachs","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.08.013_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/hup.903","article-title":"An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects","volume":"23","author":"Saiz","year":"2008","journal-title":"Hum. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2012.08.013_bib5","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/appi.ajp.158.5.802","article-title":"Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene","volume":"158","author":"Sch\u00e4fer","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2012.08.013_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.tpj.6500477","article-title":"Pharmacogenetic studies in depression: a proposal for methodologic guidelines","volume":"8","author":"Serretti","year":"2008","journal-title":"Pharmacogenomics J."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12002441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12002441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T22:21:46Z","timestamp":1542752506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X12002441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0924977X12002441"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.08.013","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}